NCT00192205View on ClinicalTrials.gov

Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

2,200

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

June 30, 2003

Conditions
Respiratory Tract Infections
Interventions
BIOLOGICAL

CAIV-T or TIV

Trial Locations (2)

Unknown

Schneider Children's Medical Center of Israel, Petah Tikva

Hospital de Txagorritxu, Vitoria-Gasteiz

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

MedImmune LLC

INDUSTRY

NCT00192205 - Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children | Biotech Hunter | Biotech Hunter